Novel and highly potent blocker of anandamide uptake (IC50
= 270 pM). Inhibits fatty acid amide hydrolase (FAAH) activity (IC50
= 12.4 nM). Following i.p. administration in rats, increases brain anandamide concentration and exerts antinociceptive effects in formalin model of pain.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold under license from Eli Lilly and Company
Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors.
Dickason-Chesterfield et al.
Cell Mol.Neurobiol., 2006;26:407
The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases.
Alexander and Cravat
Identification of a high-affinity binding site involved in the transport of endocannabinoids.
Moore et al.
The citations listed below are publications that use Tocris products. Selected citations for LY 2183240 include:
Showing Results 1 - 1 of 1